Current Neuro-Oncology

Volume 28 Number 1
10 January 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 1, 10 January

Deng B, Head R, Draaisma K, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer REM, Watts C, Angelopoulos N, Gorlia T, Bours V, Van Den Bent MJ, Robe PA, Hoogstrate Y, French PJ.
Epigenetic evolution of IDHwt glioblastomas.
Neuro Oncol. 2026 Jan 2:noaf298. doi: 10.1093/neuonc/noaf298. PMID: 41485099˰ ˍ

Shigeeda R, Shibahara I, Orihashi Y, Tanihata Y, Fujitani K, Toyoda M, Hyakutake Y, Handa H, Inukai M, Sato S, Shinoda M, Komai H, Uemasu K, Kiga T, Koizumi H, Yamamoto D, Miyasaka K, Sekiguchi T, Matsumoto C, Kusumi M, Oka H, Hide T, Kumabe T.
Retrograde longitudinal imaging analyses of IDH-wildtype glioblastoma reveal its clinical timeline from radiological birth to death.
Neurooncol Adv. 2026 Jan 2;8(1):vdaf275. doi: 10.1093/noajnl/vdaf275. PMID: 41732237. ˍ

Wu F, Yin YY, Wang D, Pan CQ, Zhai Y, Yu MC, Wang ZL, Fan WH, Zhao Z, Li GZ, Jiang T, Zhang W.
Metabolic Profiling Defines Glioblastoma Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities.
Neuro Oncol. 2026 Jan 2:noaf294. doi: 10.1093/neuonc/noaf294. PMID: 41485080. ˍ

Liu CM, Medeiros Geraldo LH, Xiao J, Sulman EP.
Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma.
J Neurooncol. 2026 Jan 3;176(2):147. doi: 10.1007/s11060-025-05388-0. PMID: 41483088˰ ˍ

Yakati V, Rao SS.
Astrocytes Protect Brain Metastatic Breast Cancer Cells From Chemotherapy Through CX43 Dependent STAT1 Signaling in Co-Culture Spheroids.
Biotechnol Bioeng. 2026 Jan 4. doi: 10.1002/bit.70144. PMID: 41486609˰ ˍ

Akbas S, Alan O, Yildiz O, Karakurt M, Yildirim EC, Colak R, Yilmaz M, Celebi A, Er O, Celayir OM, Akdag MO, Sacli O, Ozcelik M, Sahin E, Ozdemir M, Dogu GG, Demir A, Gunaltili M, Elcicek OF, Sakalar T, Karabuga B, Yildiz F, Cavdar E, Ozkan O, Ozturk AE, Akagunduz B, Kuvvet BB, Selcukbiricik F.
Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study.
J Neurooncol. 2026 Jan 5;176(2):152. doi: 10.1007/s11060-025-05415-0. PMID: 41492105˰ ˍ

Kamimura K, Nakano T, Nakajo M, Kamizono J, Hasegawa T, Tobo D, Mukai A, Kamimura Y, Ejima F, Nagano H, Takumi K, Nakajo M, Higa N, Yonezawa H, Hanaya R, Kirishima M, Tanimoto A, Otsuka H, Hirahara D, Imai H, Feiweier T, Yoshiura T.
Time-dependent diffusion-weighted imaging assessment of tumor grading and isocitrate dehydrogenase genotypes in adult-type diffuse gliomas.
Jpn J Radiol. 2026 Jan 5. doi: 10.1007/s11604-025-01936-w. PMID: 41489694. ˍ

Tsujii M, Hashimoto Y, Kaizu Y, Ohmatsu K, Kono S, Kuribayashi S.
Safety and efficacy of salvage reirradiation for recurrent high-grade gliomas: a retrospective analysis.
Jpn J Radiol. 2026 Jan 5. doi: 10.1007/s11604-025-01941-z. PMID: 41489695. ˍ

Kitagawa Y, Tanaka S, Abe H, Takami H, Hana T, Nomura M, Takayanagi S, Ushiku T, Saito N.
Histologically indolent but widely disseminated diffuse midline glioma H3K27-altered revealed by autopsy.
Brain Tumor Pathol. 2026 Jan 6. doi: 10.1007/s10014-025-00525-z. PMID: 41495345˰ ˍ

Li X, Shang X, Liu J, Zhang Y, Jia X, Li H, Wang Y, Gao J, Ma X, Zhang X, Rong X, Gan W, Zhang Y, Chen J, Wang L, Bao Z, He L, Yan X, Liu Y, Shao J, Xiao Z, Wang Z, Zhu H, Wang Z, Wu Y, Huang Y.
Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.
Nat Commun. 2026 Jan 6. doi: 10.1038/s41467-025-68112-6. PMID: 41495049. Trial registration ID: ChiCTR2000028801. ˍ

Makimoto A, Terashima K, Nishikawa R, Fujisaki H, Kurihara J, Ihara S, Adachi JI, Enokizono M, Mori N, Morikawa Y, Yuza Y.
Safety and Efficacy of Tumor-Treating Fields (TTFields) Therapy for Pediatric High-Grade Glioma: Results of a Prespecified Interim Analysis of the First Three Cases.
Children (Basel). 2026 Jan 6;13(1):84. doi: 10.3390/children13010084. PMID: 41597092. Trial registration ID: jRCTs032200423. ˍ

Qiu L, Fei Y, Ding J, Shi K, Luo J, Zhu Y, Sun X, Jiang G, Cao Y, Xu W, Zhou S.
Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single-Cell and Spatial Transcriptomics.
Ann Clin Transl Neurol. 2026 Jan 6. doi: 10.1002/acn3.70306. PMID: 41492853. ˍ

Yousefi A, Saraee E, Ghalehtaki R.
Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report.
Case Rep Oncol. 2026 Jan 7;19(1):238-247. doi: 10.1159/000549567. PMID: 41669196. Case report. ˍ

Mohand FA, Yemini S, Gorobetz-Cojocari I, Rubinstein AM, Zemel A, Kravchenko-Balasha N.
Aggressive Glioblastoma Cells Enhance the Migratory Persistence and Velocity of Less Aggressive Cells to Promote Tumor Dissemination.
Small. 2026 Jan 8:e08142. doi: 10.1002/smll.202508142. PMID: 41504001. ˍ

Park JW, Kwak J, Kim KW, Jung S, Nam CH, Kim HJ, Lee SM, Choi C, Ahn Y, Park JH, Yoo J, Shim JK, Cho HJ, Kim EH, Kim C, Ahn S, Pusch S, von Deimling A, Chang JH, Kim SH, Kim H, Ju YS, Kang SG, Lee JH.
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation.
Science. 2026 Jan 8;391(6781):eadt0559. doi: 10.1126/science.adt0559. PMID: 41505555˰ ˍ
COMMENT
Mount CW, Suvà ML. The source of IDH-mutant gliomas. Science. 2026 Jan 8;391(6781):125-126. doi: 10.1126/science.aed6843. PMID: 41505560˰ ˍ

de Jong AM, Kortman ME, Kreek MW, Flies CM, Becker AP, van der Meulen M, de Vos FYFL, Dankbaar JW, Verhoeff JJC, Robe PAJT, Snijders TJ.
Functional outcome after repeat surgery of tumor progression or treatment-associated changes in high-grade glioma: Clinical and radiological predictors.
Neurooncol Pract. 2026 Jan 9;13(4):673-684. doi: 10.1093/nop/npag002. PMID: 42453188. ˍ

Francis T, Kamath S, Kumar RM, Chakrabarti D.
Comparison of Intraoperative Hypotension Outcomes with and without Hypotension Prediction Index Tool in Patients Undergoing Brain Tumour Surgery: A Study Protocol for a Randomised Controlled Trial.
Neurol India. 2026 Jan 9;74(1):105-109. doi: 10.4103/neurol-india.Neurol-India-D-25-00367. PMID: 41510867. Trial registration ID: CTRI/2024/07/069939. ˰

Hofman R, Kemps R, Voorman JM, Aarsen FK, Partanen M.
ERNIE-Evaluating Response to an individualized Neuropsychological IntervEntion for children with brain tumors: study protocol for a randomized controlled trial.
Trials. 2026 Jan 10. doi: 10.1186/s13063-025-09420-6. PMID: 41514361. Trial registration ID: ISRCTN30985676. ˍ

Kesumayadi I, Kambe A, Kanda H, Hosoya T, Sakamoto M, Kurosaki M.
Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression.
Sci Rep. 2026 Jan 10. doi: 10.1038/s41598-026-35550-1. PMID: 41520070. ˍ